The U.S. FDA has established a new program across public, academic and private sectors to combat the COVID-19 pandemic. Designed to expedite the development of potentially safe and effective life-saving treatments, the program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, as well as support research to further evaluate whether these medical countermeasures are saf...